This segment focuses on the research, development, and commercialization of the BCAL test, a non-invasive blood test for the early detection and monitoring of breast cancer. Research and development activities include identifying and validating lipid biomarkers extracted from extracellular vesicles in blood samples. The technology utilizes in vitro diagnostic (IVD) methods to analyze these biomarkers, providing a diagnostic signature for breast cancer. The primary therapeutic area is oncology, specifically breast cancer. The patient impact is significant, offering the potential for earlier detection, improved treatment outcomes, and reduced mortality. BCAL Diagnostics aims to position itself as a leader in non-invasive breast cancer diagnostics, with a competitive advantage in its unique biomarker approach. Future opportunities include expanding the test's applications for screening and monitoring, as well as potential partnerships with clinics and healthcare providers. Regulatory and clinical aspects involve clinical trials to validate the test's accuracy and efficacy, and seeking regulatory approvals for commercialization. Partnerships with Cancer Care Associates are in place to accelerate clinical uptake.